Home > Insider Trading > Filing (0001209191-19-061189)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1510487	Principia Biopharma Inc.	PRNB	Pharmaceutical Preparations (2834)	263487603

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1751790	Stefani Wolff	C/O Principia Biopharma Inc. 220 E. Grand Avenue South San Francisco CA 94080	Chief Development Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2019-12-16	5,505	$4.54	41,114	No	4	M	Direct
Common Stock	Disposition	2019-12-16	4,205	$49.29	36,909	No	4	S	Direct
Common Stock	Disposition	2019-12-16	1,300	$49.87	35,609	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Employee Stock Option (right to buy)	Disposition	2019-12-16	5,505	$0.00	5,505	$4.54

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
24,551		2027-02-15	No	4	M	Direct

Footnotes

Includes 2,500 shares and 441 shares acquired under the Employment Stock Purchase Plan on May 15, 2019 and November 15, 2019 respectively.
The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
Represents the weighted average sales price per share. The shares sold at prices ranging from $48.81 to $49.725 per share. Upon request by the Commission staff, Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
Represents the weighted average sales price per share. The shares sold at prices ranging from $49.855 to $49.87 per share. Upon request by the Commission staff, Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
The stock option vested and became exercisable as to 25% of the shares subject to the option on July 1, 2017, and thereafter vests as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date.